Pharmacological and physiological characterization of the tremulous jaw movement model oparkinsonian tremor: Potential insights into the pathophysiology of tremor

Frontiers in Systems Neuroscience

Volumn , Issue JULY 2011, 2011, Pages

  Collins Praino, Lyndsey E ^a   Paul, Nicholas E ^a   Rychalsky, Kristen L ^a   Hinman, James R ^a   Chrobak, James J ^a   Senatus, Patrick B ^b   Salamone, John D ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Acetylcholine; Adenosine A2A; Basal ganglia; Caudate putamen; Dopamine; Muscarinic; Neostriatum; Subthalamic nucleus

Indexed keywords

3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4,6,6A,7,8,12B HEXAHYDRO 7 METHYLINDOLO[4,3 AB]PHENANTHRIDINE; ADENOSINE A2A RECEPTOR ANTAGONIST; AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; ATROPINE; BENZATROPINE; BROMOCRIPTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DIHYDREXIDINE; DIPHENHYDRAMINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GALANTAMINE; LEVODOPA; MUSCARINIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PERGOLIDE; PILOCARPINE; PIMOZIDE; QUETIAPINE; ROPINIROLE; SCOPOLAMINE; UNINDEXED DRUG;

ALZHEIMER DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MODEL; DOPAMINERGIC TRANSMISSION; HUMAN; IDIOPATHIC DISEASE; JAW MOVEMENT; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEUROCHEMISTRY; NONHUMAN; PARKINSONISM; PATHOPHYSIOLOGY; REST; REVIEW; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; SYMPTOM; TARDIVE DYSKINESIA; TREATMENT RESPONSE; TREMOR; VALIDATION STUDY;

EID: 84856204708     PISSN: 16625137     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnsys.2011.00049     Document Type: Review

References (203)

1. Aarsland, D., Hutchison, M., and Larsen, J. P. (2003). Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with demen-tia. Int. J. Geriatr. Psychiatry 18, 937-941.
2. Adams, R. D., and Victor M. (1993). "Tremors, myoclonus, spasms and tics," in eds R. D. Adams, and M. Victor. Principles of Neurology 5th edition (New York: McGraw Hill), 69-79.
3. Akai, T., Ozawa, M., Yamaguchi, M., Mizuta, E., and Kuno, S. (1995a). Combination treatment of the par-tial D2 agonist terguride with the D1 agonist SKF 82958 in 1-methyl- 4-phenyl- 1,2,3,6-tetrahydro-pyridine-lesioned parkinsonian cynomolgus monkeys. J. Pharmacol. Exp. Ther. 273, 309-314.
4. Akai, T., Ozawa, M., Yamaguchi, M., Mizuta, E., and Kuno, S. (1995b). Behavioral involvement of central dopamine D1 and D2 receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahy-dropyridine (MPTP)- lesioned parkin-sonian cynomolgus monkeys. Jpn. J. Pharmacol. 67, 117-124.
5. Alpert, M., Diamond, F., and Friedhoff, A. J. (1976). Tremorographic studies in tardive dyskinesia. Psychopharmacol. Bull. 12, 5-7.
6. Alvarez, M. V., Evidente, V. G., and Driver- Dunckley, E. D. (2007). Differentiating Parkinson's disease from other par-kinsonian disorders. Semin. Neurol. 27, 356-362.
7. Aquilonius, S. M. (1980). "Cholinergic mechanisms in the CNS related to Parkinson's disease," in Parkinson's Disease-Current Progress, Problems and Management, eds U. K. Rinne, M. Klinger, and Stamm, G.(North Holland: Elsevier), 17-27.
8. Arai, M. (2000). Parkinsonism onset in a patient concurrently using tiapride and donepezil. Intern. Med. 39, 863.
9. Ashkan, K., Wallace, B., Bell, B. A., and Benabid, A. L. (2004). Deep brain stimulation of the subthalamic nucleus in Parkinson's Disease 1993- 2003: where are we 10 years on? Br. J. Neurosurg. 18, 19-34.
10. Bara-Jimenez, W., Sherzai, A., Dimitrova, T., Favit, A., Bibbiani, F., Gillespie, M., Morris, M. J., Mouradian, M. M., and Chase, T. N. (2003). Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 61, 293-296.
11. Barbeau, A. (1986). "Parkinson's disease: clinical features and etiopathology," in Handbook of Clinical Neurology, Vol. 5 Extrapyramidal Disorders, eds P. J. Vinken, G. W. Bruyn, and I. Klawans, II (North Holland: Elsevier), 87-152.
12. Baskin, P., Gianutsos, G., and Salamone, J. D. (1994). Repeated scopolamine injections sensitize rats to pilocarpine- induced vacuous jaw movements and enhance striatal muscarinic receptor binding. Pharmacol. Biochem. Behav. 49, 437-442.
13. Baskin, P., and Salamone, J. D. (1993). Vacuous jaw movements in rats induced by acute reserpine admin-istration: interactions with different doses of apomorphine. Pharmacol. Biochem. Behav. 46, 793-797.
14. Benabid, A. L., Pollak, P., Gross, C., Hoffmann, D., Benazzouz, A., Gao, D. M., Laurent, A., Gentil, M., and Perret, J. (1994). Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease. Stereotact. Funct. Neurosurg. 62, 76-84.
15. Benazzouz, A., Boraud, T., Feger, J., Burbaud, P., Bioulac, B., and Gross, C. (1996). Alleviation of experimental hemiparkinsonism by highfrequency stimulation of the subthalamic nucleus in primates: a comparison with l-DOPA treatment. Mov. Disord. 11, 627-632.
16. Benazzouz, A., Gross, C., Feger, J., Boraud, T., and Bioulac, B. (1993). Reversal of neuro-rigidity and improvement in motor performance by subthalamic high- frequency stimulation in MPTP- treated monkeys. Eur. J. Neurosci. 5, 382-389.
17. Ben-Pazi, H., Bergman, H., Goldberg, J. A., Giladi, N., Hansel, D., Reches, A., and Simon, E. S. (2001). Synchrony of rest tremor in multiple limbs in Parkinson's disease: evidence for mul-tiple oscillators. J. Neural Transm. 108, 287-296.
18. Bergman, H., and Deuschl, G. (2002). Pathophysiology of Parkinson's dis-ease: from clinical neurology to basic neuroscience and back. Mov. Disord. 17(Suppl. 3), s28-s40.
19. Bergman, H., Feingold, A., Nini, A., Raz, A., Slovin, H., Abeles, M., and Vaadia, E. (1998). Physiological aspects of information processing in the basal ganglia of normal and parkinsonian patients. Trends Neurosci. 21, 32-38.
20. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., and Seitelberger, F. (1973). Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20, 415-455.
21. Betz, A., Ishiwari, K., Wisniecki, A., Huyn, N., and Salamone, J. D. (2005). Quetiapine (Seroquel) shows a pat-tern of behavioral effects similar to the atypical antipsychotics clozap-ine and olanzapine: studies with tremulous jaw movements in rats. Psychopharmacology (Berl.) 179, 383-392.
22. Betz, A. J., McLaughlin, P. J., Burgos, M., Weber, S. M., and Salamone, J. D. (2007). The muscarinic recep-tor antagonist tropicamide sup-presses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 recep-tors. Psychopharmacology (Berl.) 194, 347-359.
23. Betz, A. J., Vontell, R., Valenta, J., Worden, L., Sink, K. S., Font, L., Correa, M., Sager, T. N., and Salamone, J. D. (2009). Effects of the adenosine A2A antagonist KW-6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropi-camide. Neuroscience 163, 97-108.
24. Bevan, M. D., Magill, P. J., Terman, D., Bolam, J. P., and Wilson, C. J. (2002). Move to the rhythm: oscillations in the subthalamic nucleus-external globus pallidus network. Trends Neurosci. 25, 525-531.
25. Binder, S., Deuschl, G., and Volkmann, J. (2009). Effect of cabergoline on parkinsonian tremor assessed by long-term actigraphy. Eur. Neurol. 61, 149-153.
26. Bourke, D., and Drukenbrod, R. W. (1998). Possible association between donepezil and worsening Parkinson's disease. Ann. Pharmacother. 32, 610-611.
27. Boyce, S., Rupniak, N. M., Steventon, M. J., and Iversen, S. D. (1990). Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. Neurology 40, 927-933.
28. Braun, A., Fabbrini, G., Mouradian, M. M., Serrati, C., Barone, P., and Chase, T. (1987). Selective D-1 dopamine recep-tor agonist treatment of Parkinson's disease. J. Neural Transm. 68, 41-50.
29. Brown, P. (2003). Oscillatory nature of human basal ganglia activity: rela-tionship to the pathophysiology of Parkinson's disease. Mov. Disord. 18, 357-363.
30. Brown, P., Oliviero, A., Mazzone, P., Insola, A., Tonali, P., and Di Lazzaro, V. (2001). Dopamine dependency of oscilla-tions between subthalamic nucleus and pallidum in Parkinson's disease. J. Neurosci. 21, 1033-1038
31. Burnett, G. B., Prange, A. J., Wilson, I. C., Jolli, L. A., Creese, I. C., and Snyder, S. H. (1980). Adverse effects of anti-cholinergic antiparkinsonian drugs in tardive dyskinesia. Neuropsychobiology 6, 109-120.
32. Calabresi, P., Centonze, D., Gubellini, P., Pisani, A., and Bernardi, G. (2000). Acetylcholine-mediated modulation of striatal function. Trends Neurosci. 23, 120-126.
33. Calabresi, P., Picconi, B., Parnetti, L., and Di Filippo, M. (2006). A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurol. 5, 974-983.
34. Carlson, B. B., Behrstock, S., Tobin, A. J., and Salamone, J. D. (2003a). Brain implantations of engineered GABA- releasing cells suppress tremor in an animal model of parkinsonism. Neuroscience 119, 927-932.
35. Carlson, B. B., Wisniecki, A., and Salamone, J. D. (2003b). Local injec-tions of the 5-hydroxytryptamine antagonist mianserin into substantia nigra pars reticulara block tremulous jaw movements in rats: studies with a putative model of parkinsonian tremor. Psychopharmacology (Berl.) 165, 229-237.
36. Carlson, B. B., Trevitt, J. T., and Salamone, J. D. (2000). Effects of H1 antago-nists on cholinomimetic-induced tremulous jaw movements: studies of diphenhydramine, doxepin, and mepy-ramine. Pharmacol. Biochem. Behav. 65, 683-689.
37. Cenci, M. A., Whishaw, I. Q., and Schallert, T. (2002). Animal models of neuro-neurophys-logical deficits: how relevant is the rat? Nat. Rev. Neurosci. 3, 574-579.
38. Chen, J. F., Moratalla, R., Impagnatiello, F., Grandy, D. K., Cuellar, B., Rubinstein, M., Beilstein, M. A., Hacket, E., Fink, J. S., Low, M. J., Ongini, E., and Schwarzschild, M. A. (2001). The role of the D2 dopamine receptor (D2R) in A2A adenenosine-receptor (A2aR) mediated behavioral and cel-lular responses as revealed by A2A and D2 receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 98, 1970-1975.
39. Chesler, E., and Salamone, J. (1996). Effects of acute and repeated clozapine injec-tions on cholinomimetic-induced vacuous jaw movements. Pharmacol. Biochem. Behav. 54, 619-624.
40. Close, S. P., Elliott, P. J., Hayes, A. G., and Marriott, A. S. (1990). Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's dis-ease. Psychopharmacology (Berl.) 102, 295-300.
41. Collins, L. E., Galtieri, D. J., Brennum, L. T., Sager, T. N., Hockemeyer, J., Müller, C. E., Hinman, J. R., Chrobak, J. J., and Salamone, J. D. (2010a). Cholinomimetic-induced tremulous jaw movements are suppressed by the adenosine A2A antagonists MSX-3 and SCH58261, but not the adeno-sine A1 antagonist DPCPX: possible relevance for drug-induced parkin-sonism. Pharmacol. Biochem. Behav. 94, 561-569.
42. Collins, L. E., Galtieri, D. J., Collins, P., Jones, S. K., Port, R. G., Paul, N. E., Hockemeyer, J., Muller, C. E., and Salamone, J. D. (2010b). Interactions between adenosine and dopamine receptor antagonists with different selectivity profiles: effects on loco-motor activity. Behav. Brain Res. 211, 148-155.
43. Collins, L. E., Chrobak, J. J., and Salamone, J. D. (2010c). The char-acterization of electromyographic and EEG activity in the tremulous jaw movement model: the use of time series analysis to investigate the pathophysiology of parkin-sonian resting tremor. Society for Neuroscience Annual Meeting Abstract Locator, San Diego, CA.
44. Collins, L. E., Paul, N. E., Abbas, S. F., Leser C. E., Galtieri, D. J., Chrobak, J. J., Baqi, Y., Muller, C. E., and Salamone J. D. (2011). Oral tremor induced by galantamine in rats: a model of the parkinsonian side effects of cholino-mimetics used to treat Alzheimer's disease. Pharmacol. Biochem. Behav. 99, 414-422.
45. Collins-Praino, L. E., Paul, N. E., Ledgard, F., Podurgiel, S., Kovner, R., Satzer, D., McPherson, M., Rhodes, C., Hussain, N., Huber, M., Salamone, J. D., and Senatus, P. B. (2011a). Effect of subthalamic nucleus deep brain stimulation on drug-induced tremulous jaw move-ments. (In preparation).
46. Collins-Praino, L. E., Pennarolla, A., Port, R. G., Sager, T. N., and Salamone, J. D. (2011b). The novel adenosine antago-nist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade. (Submitted).
47. Correa, M., Wisniecki, A., Betz, A., Dobson, D. R., O'Neill, M. F., O'Neill, M. J., and Salamone, J. D. (2004). The adenosine A2A antagonist KF 17837 reverses the locomotor suppres-sion and tremulous jaw movements induced by haloperidol in rats: possi-ble relevance to parkinsonism. Behav. Brain Res. 148, 47-54.
48. Courtenmance, R., Fujii, N., and Graybiel, A. M. (2003). Synchronous, focally modulated beta-band oscillations characterize local field potential activity in the striatum of awake behaving monkeys. J. Neurosci. 23, 11741-11752.
49. Cousins, M. S., Atherton, A., and Salamone, J. D. (1998). Behavioral and electromyographic characterization of the local frequency of tacrine-induced tremulous jaw movements. Physiol. Behav. 64, 153-158.
50. Cousins, M. S., Carriero, D. L., and Salamone, J. D. (1997). Tremulous jaw movements induced by the ace-tylcholinesterase inhibitor tacrine: effects of antiparkinsonian drugs. Eur. J. Pharmacol. 322, 137-145.
51. Cousins, M. S., Finn, M., Trevitt, J., Carriero, D. L., Conlan, A., and Salamone, J. D. (1999). The role of ventrolateral striatal acetylcholine in the production of tacrine-induced jaw movements. Pharmacol. Biochem. Behav. 62, 439-447.
52. Cousins, M. S., and Salamone, J. D. (1996). Involvement of ventrolateral striatal dopamine in movement initiation and execution: a microdialysis and behavioral investigation. Neuroscience 70, 849-859.
53. Cragg, S. J. (2006). Meaningful silences: how dopamine listens to the Ach pause. Trends Neurosci. 29, 125-131.
54. Creed, M., Hamani, C., and Nobrega, J. N. (2010). Deep brain stimulation of the subthalamic or entopedun-cular nucleus attenuates vacuous chewing movements in a rodent model of tardive dyskinesia. Eur. Neuropsychopharmacol. 21, 393-400.
55. DeLong, M. R. (1990). Primate model of movement disorders of basal ganglia origin. Trends Neurosci. 13, 281-285.
56. Deuschl, G., Krack, P., Lauk, M., and Timmer, J. (1996). Clinical neurophysiology of tremor. J. Clin. Neurophysiol. 13, 110-121.
57. DeLong, M. R. (1990). Primate model of movement disorders of basal ganglia origin. Trends Neurosci. 13, 281-285.
58. Deuschl, G., Krack, P., Lauk, M., and Timmer, J. (1996). Clinical neurophys-iology of tremor. J. Clin. Neurophysiol. 13, 110-121.
59. Deuschl, G., Raethjen, J., Baron, R., Lindemann, M., Wilms, H., and Krack, P. (2000). The pathophysiology of par-kinsonian tremor: a review. J. Neurol. 247(Suppl. 5), 8/33-8/48.
60. Deuschl, G., Raethjen, J., Lindemann, M., and Krack, P. (2001). The patho-physiology of tremor. A review. Muscle Nerve 24, 716-735.
61. Duvoisin, R. C. (1967). Cholinergic- anticholinergic antagonism in parkinsonism. Arch. Neurol. 17, 124-136.
62. Egan, M. F., Hurd, Y., Ferguson, J., Bachus, S. E., Hamid, E. H., and Hyde, T. M. (1996). Pharmacological and neu-rochemical differences between acute and tardive vacuous chewing movements induced by haloperi-dol. Psychopharmacology (Berl.) 127, 337-345.
63. Elbe, R. J., and Koller, W. C. (1990). Tremor. Baltimore, MD: Johns Hopkins University Press.
64. Ellison, G., and See, R. (1989). Rats admin-istered chronic neuroleptics develop oral movements which are similar in form to those in humans with tar-dive dyskinesia. Psychopharmacology (Berl.) 98, 564-566.
65. Ellison, G., See, R., Levin, E., and Kinney, J. (1987). Tremorous mouth move-ments in rats administered chronic neuroleptics. Psychopharmacology 92, 122-126.
66. Factor, S., Mark, M. H., Watts, R., Struck, L., Mori, A., Ballerini, R., Sussman, N. M., and Istradefylline 6002-US-007 Study Group. (2010). A long-term study of istradefylline in subjects with fluctuating Parkinson's dis-ease. Parkinsonism Relat. Disord. 16, 423-426.
67. Fahn, W. E., Lake, C. R., and Gerber, C. J. (1974). Cholinergic suppression of tar-dive dyskinesia. Psychopharmacology (Berl.) 42, 135-137.
68. Fernandez, H. H., Greeley, D. R., Zweig, R. M., Wojcieszek, J., Mori, A., and Sussman, N. M. (2010). Istradefylline as monotherapy for Parkinson dis-ease: results of the 6002-US-051 trial. Parkinsonism Relat. Disord. 16, 16-20.
69. Ferré, S., Ciruela, F., Canals, M., Marcellino, D., Burgueno, J., Casado, V., Hillion, J., Torvinen, M., Fanelli, F., Benedetti, Pd. P., Goldberg, S. R., Bouvier, M., Fuxe, K., Agnati, L. F., Lluis, C., Franco, R., and Woods, A. (2004). Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat. Disord. 10, 265-271.
70. Ferré, S., Freidholm, B. B., Morelli, M., Popoli, P., and Fuxe, K. (1997). Adenosine-dopamine receptor- receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20, 482-487.
71. Findley, L. J. (1988). "Tremors: dif-ferential diagnosis and pharma-cology," in Parkinson's Disease and Movement Disorders, eds J. Jankovic and E. Tolosa (Baltimore: Urban and Schwarzenberg), 243-262.
72. Findley, L. J., and Capildeo, R. (1984). Movement Disorders: Tremor. Oxford: Oxford University Press.
73. Findley, L. J., and Gresty, M. A. (1981). Tremor. Br. J. Hosp. Med. 26, 16-32.
74. Findley, L. J., and Gresty, M. A. (1988). Head, facial, and voice tremor. Adv. Neurol. 49, 239-253.
75. Findley, L. J., Gresty, M. A., and Halmagyi, G. M. (1981). Tremor, the cogwheel phenomenon and clo-nus in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 44, 534-546.
76. Finn, M., Mayorga, A. J., Conlan, A., and Salamone, J. D. (1997a). Involvement of pallidal and nigral GABA mecha-nisms in the generation of tremulous jaw movements in rats. Neuroscience 80, 532-544.
77. Finn, M., Jassen, A., Baskin, P., and Salamone, J. D. (1997b). Tremulous characteristic of vacuous jaw move-ments induced by pilocarpine and ventrolateral striatal dopamine deple-tions. Pharmacol. Biochem. Behav. 57, 243-249.
78. Galtieri, D. J., Collins, L. E., Paul, N. E., and Salamone, J. D. (2010). Subchronic administration of the dopamine D1 antagonist SCH 39166 (ecopipam) induces parkinso-nian motor impairment in a rodent model of parkinsonism: potential role of the direct pathway. Society for Neuroscience Annual Meeting Abstract Locator, San Diego, CA.
79. Gillespie, R. J., Bamford, S. J., Gaur, S., Jordan, A. M., Lerpiniere, J., Mansell, H. L., and Stratton, G. C. (2009). Antagonists of the human A(2A) receptor. Part 5: highly bio-available pyrimidine-4-carboxamides. Bioorg. Med. Chem. Lett. 19, 2664-2667.
80. Glassman, R. B., and Glassman, H. N. (1980). Oral dyskinesia in brain-dam-aged rats withdrawn from neurolep-tics: implication for models of tardive dyskinesia. Psychopharmacology (Berl.) 69, 19-25.
81. Gnanalingham, K. K., Erol, D. D., Hunter, A. J., Smith, L. A., Jenner, P., and Marsden, C. D. (1995). Differential anti-parkin-sonian effects of benzazepine D1 dopa-mine agonists with varying efficacies co-administered with quinpirole in pri-mate and rodent models of Parkinson's disease. Psychopharmacology (Berl.) 117, 287-297.
82. Gurevich, T. Y., Shabtai, H., Korczyn, A. D., Simon, E. S., and Giladi, N. (2006). Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia. Mov. Disord. 21, 1663-1666.
83. Halliday, D. M., Rosenberg, J. R., Amjad, A. M., Breeze, B., Conway, B. A., and Farmer, S. F. (1995). A framework for the analysis of mixed time series/point process data-theory and application to the study of physiological tremor, single motor unit discharges, and elec-tromyograms. Prog. Biophys. Mo. Biol. 64, 237-278.
84. Hammond, C., Bergman, H., and Brown, P. (2007). Pathological synchroniza-tion in Parkinson's disease: networks, models and treatments. Trends Neurosci. 30, 357-364.
85. Hauber, W., Nagel, J., Sauer, R., and Muller, C. E. (1998). Motor effects induced by a blockade of adenosine A2A receptors in the caudate-putamen. Neuroreport 9, 1803-1806.
86. Hauser, R. A., Hubble, J. P., Truong, D. D., and Istradefylline US-001 Study Group. (2003). Randomized trial of the adenosine A(2A) receptor antag-onist istradefylline in advanced PD. Neurology 61, 297-303.
87. Hauser, R. A., Shulman, L. M., Trugman, J. M., Roberts, J. W., Mori, A., Ballerini, R., Sussman, N. M., and Istradefylline 6002-US-013 Study Group. (2008). Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov. Disord. 23, 2177-2185.
88. Hersch, S. M., Gutekunst, C. A., Rees, H. D., Heilman, C. J., and Levey, A. I. (1994). Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies. J. Neurosci. 14, 3351-3363.
89. Hoehn, M. M., and Yahr, M. D. (1967). Parkinsonism: onset, progression, and mortality. Neurology 17, 427-442.
90. Hornykiewicz, O. (1972). "Dopamine and its physiological significance in brain function," in The Structure and Function of Nervous Tissue, ed. G. H. Browne (New York: Academic Press), 367-414.
91. Hornykiewicz, O. (1973). Dopamine in the basal ganglia. Br. Med. Bull. 29, 172-178.
92. Hunker, C. J., and Abbs, J. H. (1990). Uniform frequency of parkinsonian resting tremor in the lips, jaw, tongue and index finger. Mov. Disord. 5, 71-77.
93. Hurtado, J. M., Lachaux, J. P., Beckley, D. J., Gray, C. M., and Sigvardt, K. A. (2000). Inter- and intralimb oscillator coupling in parkinsonian tremor. Mov. Disord. 15, 683-691.
94. Kelley, A. E., Bakshi, V. P., Delfs, J. M., and Lang, C. G. (1989). Cholinergic stimulation of the ventrolateral striatum elicits mouth movements in rats: pharmacological and regional speci-ficity. Psychopharmacology (Berl.) 99, 542-549.
95. Kikuchi de Beltran, K., Koshikawa, N., Saigusa, T., Watanabe, K., Koshida, Y., and Kobayashi, M. (1992). Cholinergic/dopaminergic inter-action in the rat striatum assessed from drug-induced repetitive oral movements. Eur. J. Pharmacol. 214, 181-189.
96. Knebel, W., Rao, N., Uchimura, T., Mori, A., Fisher, J., Gastonguay, M. R., and Chaikin, P. (2011). Population phar-macokinetic analysis of istradefylline in healthy subjects and in patients with Parkinson's disease. J. Clin. Pharmacol. 51, 40-52.
97. Koller, W. C. (2002). Treatment of early Parkinson's disease. Neurology 58, S79-S86.
98. Koster, B., Lauk, M., Timmer, J., and Lucking, C. H. (1997). Side to side correlation of pathological tremors. Electroencephalogr. Clin. Neurophysiol. 103, 211-220.
99. Leventoglu, A., and Baysal, A. I. (2008). Benign tremulous Parkinson's disease. Acta Neurol. Belg. 108, 48-52.
100. Levy, R., Ashby, P., Hutchison, W. D., Lang, A. E., Lozano, A. M., and Dostrovsky, J. O. (2002). Dependence of subthalamic nucleus oscillation on movement and dopamine in Parkinson's disease. Brain 125, 1196-1209.
101. LeWitt, P. A., Guttman, M., Tetrud, J. W., Tuite, P. J., Mori, A., Chaikin, P., Sussman, N. M., 6002-US-005 Study Group. (2008). Adenosine A2A receptor antagonist istradefyl-line (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann. Neurol. 63, 295-302.
102. Limousin, P., Krack, P., Pollak, P., Benazzouz, A., Ardouin, C., Hoffnann, D., and Benabid, A. L. (1998). Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N. Engl. J. Med. 339, 1105-1111.
103. Limousin, P., Pollak, P., Benazzouz, A., Hoffmann, D., Le Bas, J. F., Broussolle, E., Perret, J. E., and Benabid, A. L. (1995). Effect of Parkinsonian signs and symptoms of bilateral subtha-lamic nucleus stimulation. Lancet 345, 91-95.
104. Litvinenko, I. V., Odinak, M. M., Mogilnaya, V. I., and Emelin, A. Y. (2008). Efficacy and safety of gal-antamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial). Neurosci. Behav. Physiol. 38, 937-945.
105. Mansur, P. H. G., Cury, L. K. P., Andrade, A. O., Pereira, A. A., Miotto, G. A., Soares, A. B., and Naves, E. L. (2007). A review of techniques for tremor recording and quantification. Crit. Rev. Biomed. Eng. 35, 343-362.
106. Marsden, C. (1984). "Origins of nor-mal and pathological tremor," in Movement Disorders: Tremor, eds L. Findley and R. Capildeo (London: Butterworth), 37-84.
107. Masimore, B., Schmitzer-Torbert, N. C., Kakalios, J., and Redish, A. D. (2005). Transient striatal gamma local field potentials signal movement initiation in rats. Neuroreport 16, 2021-2024.
108. Mayorga, A. J., Carriero, D. L., Cousins, M. S., Gianutsos, G., and Salamone, J. D. (1997). Tremulous jaw movements produced by acute tacrine adminis-tration: possible relation to parkinso-nian side effects. Pharmacol. Biochem. Behav. 56, 273-279.
109. Mayorga, A. J., Trevitt, J. T., Conlan, A., Ginutsos, G., and Salamone, J. D. (1999a). Striatal and nigral D1 mechanisms involved in the antipar-kinsonian effects of SKF 82958 (APB): studies of tremulous jaw movements in rats. Psychopharmacology 143, 72-81.
110. Mayorga, A. J., Gianutsos, G., and Salamone, J. D. (1999b). Effects of striatal injections of 8-bromo-cyclic- AMP on pilocarpine-induced tremu-lous jaw movements in rats. Brain Res. 829, 180-184.
111. Mayorga, A. J., Cousins, M. S. Conlan, A. Gianutsos, G., and Salamone, J. D. (1999c). Characterization of the mus-carinic receptor subtype mediating pilocarpine-induced tremulous jaw movements in rats. Eur. J. Pharmacol. 364, 7-11.
112. McCain, K. R., Sawyer, T. S., and Spiller, H. A. (2007). Evaluation of centrally acting cholinesterase inhibitor expo-sures in adults. Ann. Pharmacother. 41, 1632-1637.
113. McEvoy, J. P. (1983). The clinical use of anticholinergic drugs as treatments for extrapyramidal side effects of neuro-leptic drugs. J. Clin. Psychpharmacol. 3, 288-302.
114. McGeorge, A. J., and Faull, R. L. M. (1989). Organization of the projec-tion from the cerebral cortex to the striatum in the rat. Neuroscience 29, 503-537.
115. McSwain, M. L., and Forman, L. M. (1995). Severe parkinsonian symptom development on combination treat-ment with tacrine and haloperidol. J. Clin. Psychopharmacol. 15, 284.
116. Milanov, I. (2001). Electromyographic differentiation of tremors. Clin. Neurophysiol. 112, 1626-1632.
117. Miwa, H., Hama, K., Kajimoto, Y., and Kondo, T. (2008). Effects of zon-isamide on experimental tremors inrats. Parkinsonism Relat. Disord. 14, 33-36.
118. Miwa, H., Koh, J., Kajimoto, Y., and Kondo, T. (2011). Effects of T-type cal-cium channel blockers on a parkinso-nian tremor model in rats. Pharmacol. Biochem. Behav. 97, 656-659.
119. Miwa, H., Kubo, T., Suzuki, A., and Kondo, T. (2009). Effects of zonisamide on c-Fos expression under conditions of tacrine-induced tremulous jaw move-ments in rats: a potential mechanism underlying its anti-parkinsonian tremor effect. Parkinsonism Relat. Disord. 15, 30-35.
120. Mizuno, Y., Hasegawa, K., Kondo, T., Kuno, S., and Yamamoto, M. (2010). Clinical efficacy of istradefylline (KW- 6002) in Parkinson's disease: a rand-omized, controlled study. Mov. Disord. 25, 1437-1443.
121. Morelli, M., Di Paolo, T., Wardas, J., Calon, F., Xiao, D., and Schwarzschild, M. A. (2007). Role of adenosine A2A recep-tors in parkinsonian motor impair-ment and l-DOPA-induced motor complications. Prog. Neurobiol. 83, 293-309.
122. Morelli, M., and Pinna, A. (2001). Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease. Neurol. Sci. 22, 71-72.
123. Morris, G., Arkadir, D., Nevet, A., Vaadia, E., and Bergman, H. (2004). Coincident but distinct messages of midbrain dopamine and striatal tonically active neurons. Neuron 43, 133-143.
124. Morrison, S., Kerr, G., and Silburn, P. (2008). Bilateral tremor relations in Parkinson's disease: effects of mechanical coupling and medica-tion. Parkinsonism Relat. Disord. 14, 298-308.
125. Muthuraman, M., Govindan, R. B., Deuschl, G., Heute, U., and Raethjen, J. (2008). Differentiating phase shift and delay in narrow band coherent signals. Clin. Neurophysiol. 119, 1062-1070.
126. Navan, P., Findley, L. J., Jeffs, J. A., Pearce, R. K., and Bain, P. G. (2003). Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on parkinsonian tremor. Mov. Disord. 18, 1324-1331.
127. Navan, P., Findley, L. J., Undy, M. B., Pearce, R. K., and Bain, P. G. (2005). A randomly assigned double-blind cross-over study examining the rela-tive anti-parkinsonian tremor effects of pramipexole and pergolide. Eur. J. Neurol. 12, 1-8.
128. Noring, U., Povlesen, U. J., Casey, D. E., and Gerlach, J. (1984). Effect of a cholinomimetic drug (RS 86) in tardive dyskinesia and drugrelatedparkinsonism. Psychopharmacology 84, 569-571.
129. Obeso, J. A., Rodríguez-Oroz, M. C., Benitez-Temino, B., Blesa, F. J., Guridi, J., Marin, C., and Rodriguez, M. (2008). Functional organization of the basal ganglia: therapeutic impli-cations for Parkinson's disease. Mov. Disord. 23, S548-S559.
130. Obeso, J. A., Rodrigquez-Oroz, M. C., Rodriguez, M., Lanciego, J. L., Artieda, J., Gonzolo, N., and Olnow, C. W. (2000). Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci. 23, S8-S19.
131. Olianas, M. C., Adem, A., Karlsson, E., and Onali, P. (1996). Rat striatal muscarinic receptors coupled to the inhibition of adenylyl cyclase activ-ity: potent block by the selective m4 ligand muscarinic toxin 3 (MT3). Br. J. Pharmacol. 118, 283-238.
132. Olianas, M. C., and Onali, P. (1999). PD 102807, a novel muscarinic M4 recep-tor antagonist, discriminates between striatal and cortical muscarinic recep-tors coupled to cyclic AMP. Life Sci. 65, 2233-2240.
133. O'Suilleabhain, P. E., and Matsumoto, J. Y. (1998). Time-frequency analysis of tremors. Brain 121, 2127-2134.
134. Ott, B. R., and Lannon, M. C. (1992). Exacerbation of Parkinsonism by tacrine. Clin. Neuropharmacol. 15, 322-325.
135. Pellegrino, L. J., Pellegrino, A. S., and Cushman, A. J. (1979). A Stereotaxic Atlas of the Rat Brain. New York: Plenum.
136. Pessiglione, M., Guehl, D., Rolland, A. S., Francios, C., Hirsch, E. C., Feger, J., and Tremblay, L. (2005). Thalamic neu-ronal activity in dopamine-depleted primates:evidence for a loss of func-tional segregation within basal ganglia circuits. J. Neurosci. 25, 1523-1531.
137. Pinna, A. (2009). Novel investigational adenosine A2A receptor antagonists for Parkinson's disease. Expert Opin. Investig. Drugs 18, 1619-1631.
138. Pinna, A., Schintu, N., Simola, N., Volpini, R., Pontis, S., Cristalli, G., and Morelli, M. (2010). A new ethylad-enine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinso-nian drug. Neuropharmacology 58, 613-623.
139. Pisa, M. (1988). Motor somatotopy in the striatum of rat: manipulation, biting and gait. Behav. Brain Res. 27, 21-35.
140. Pisani, A., Bernardi, G., Ding, J., and Surmeier, D. J. (2007). Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci. 30, 545-553.
141. Pisani, A., Bonsi, P., Centonze, D., Gubellini, P., Bernardi, G., andCalabresi, P. (2003). Targeting striatal cholinergic interneurons in Parkinson's disease: focus on metabotropic glutamate receptors. Neuropharmacology 45, 45-56.
142. Raethjen, J., Govindan, R. B., Muthuraman, M., Kopper, F., Volkmann, J., and Deuschl, G. (2009). Cortical correlates of the basic and first harmonic frequency of Parkinsonian tremor. Clin. Neurophysiol. 120, 1866-1872.
143. Raethjen, J., Lindemann, M., Schmaljohann, H., Wenzelburger, R., Pfister, G., and Deuschl, G. (2000). Multiple oscillators are causing par-kinsonian and essential tremor. Mov. Disord. 15, 84-94
144. Reck, C., Florin, E., Wojtecki, L., Krause, H., Groiss, S., Voges, J., Maarouf, M., Sturm, V., Schnitzler, A., and Timmermann, L. (2009). Characterization of tremor-associated local field potentials in the subtha-lamic nucleus in Parkinson's disease. Eur. J. Neurosci. 29, 599-612.
145. Rodriguez Diaz, M., Abdala, P., Barroso- Chinea, P., Obeso, J., and Gonzalez- Hernandez, T. (2001). Motor behavioural changes after intracere-broventricular injection of 6-hydroxy-dopamine in the rat: an animal model of Parkinson's disease. Behav. Brain Res. 122, 79-92.
146. Rosin, D. L., Robeva, A., Woodard, R. L., Guyenet, P. G., and Linden, J. (1998). Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J. Comp. Neurol. 401, 163-186.
147. Rupniak, N. M., Jenner, P., and Marsden, C. D. (1986). Acute dys-tonia induced by neuroleptic drugs. Psychopharmacology 88, 403-419.
148. Rupniak, N. M. J., Jenner, P., and Marsden, C. D. (1983). Cholinergic modula-tion of perioral behavior induced by chronic neuroleptic administration to rats. Psychopharmacology (Berl.) 79, 226-230.
149. Rupniak, N. M. J., Jenner, P., and Marsden, C. D. (1985). Pharmacological characterization of spontaneous or drug-induced purposeless chewing movements in rats. Psychopharmacology (Berl.) 85, 71-79.
150. Salamone, J. D. (2010). Preladenant, a novel adenosine A(2A) receptor antagonist for the potential treatment of parkinsonism and other disorders. Idrugs 13, 723-731.
151. Salamone, J. D., and Baskin, P. (1996). Vacuous jaw movements induced by acute reserpine and low-dose apomor-phine: possible model of parkinsonian tremor. Pharmacol. Biochem. Behav. 53, 179-183.
152. Salamone, J. D., Betz, A. J., Ishiwari, K., Felsted, J., Madson, L., Mirante, B., Clark, K., Font, L., Korbey, S., Sager, T. N., Hockemeyer, J., and Muller, C. E. (2008a). Tremorolytic effects of adenosine A2A antagonists: implica-tions for parkinsonism. Front. Biosci. 13, 3594-3605.
153. Salamone, J. D., Ishiwari, K., Betz, A. J., Farrar, A. M., Mingote, S. M., Font, L., Hockemeyer, J., Müller, C. E., and Correa, M. (2008b). Dopamine/ adenosine interactions related to locomotion and tremor in animal models: possible relevance to parkin-sonism. Parkinsonism Relat. Disord. 14, S130-S134.
154. Salamone, J. D., Carlson, B. B., Rios, C., Lentini, E., Correa, M., Wisniecki, A., and Betz, A. (2005). Dopamine agonists suppress cholinomimetic- induced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, rop-inirole and CY 208-243. Behav. Brain Res. 156, 173-179.
155. Salamone, J. D., Correa, M., Carlson, B., Wisniecki, A., Mayorga, A., Nisenbaum, E., Nisenbaum, L., and Felder, C. (2001). Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents. Implications for cholinergic involvement in parkinsonism. Life Sci. 68, 2579-2584.
156. Salamone, J. D., Johnson, C. J., McCullough, L. D., and Steinpreis, R. E. (1990). Lateral striatal cho-linergic mechanisms involved in oral motor activities in the rat. Psychopharmacology 102, 529-534.
157. Salamone, J. D., Kurth, P. A., McCullough, L. D., Sokolowski, J. D., and Cousins, M. S. (1993a). The role of brain dopa-mine in response initiation: effects of haloperidol and regionally-specific dopamine depletions on the local rate of instrumental responding. Brain Res. 628, 218-226.
158. Salamone, J. D., Mahan, K., and Rogers, S. (1993b). Ventrolateral striatal dopa-mine depletions impair feeding and food handling in rats. Pharmacol. Biochem. Behav. 44, 605-610.
159. Salamone, J. D., Lalies, M. D., Channell, S. L., and Iversen, S. D. (1986). Behavioural and pharmacological characterization of the mouth move-ments induced by muscarinic ago-nists in the rat. Psychopharmacology 88, 467-471.
160. Salamone, J. D., Mayorga, A. J., Trevitt, J. T., Cousins, M. S., Conlan, A., and Nawab, A. (1998). Tremulous jaw movements in rats: a model of par-kinsonian tremor. Prog. Neurobiol. 56, 591-611.
161. Santiago, M. P., and Potter, L. T. (2001). Biotinylated m4-toxin demonstrates more M4 muscarinic receptor protein on direct than indirect striatal projec-tion neurons. Brain Res. 894, 12-20.
162. Schneider, S. A., Edwards, M. J., Cordivari, C., Macleod, W. N., and Bhatia, K. P. (2006). Botulinum toxin A may be effi-cacious as treatment for jaw tremor in Parkinson's disease. Mov. Disord. 21, 1722-1724.
163. Schrag, A., Keens, J., Warner, J., and Ropinirole Study Group. (2002). Ropinirole for the treatment of tremor in early Parkinson's disease. Eur. J. Neurol. 9, 253-257.
164. Schrag, A., Schelosky, L., Scholz, U., and Poewe, W. (1999). Reduction of Parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single-dose challenges. Mov. Disord. 14, 252-255.
165. See, R., and Chapman, M. (1991). Cholinergic modulation of oral activity in drug-naive and chronic haloperidol-treated rats. Pharmacol. Biochem. Behav. 39, 49-54.
166. Selby, G. (1986). "Parkinson's disease," in Handbook of Clinical Neurology, eds P. Vinken and G. W. Bruyn (New York: Wiley), 173-211.
167. Shea, C., MacKnight, C., and Rockwood, K. (1998). Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int. Psychogerniatr. 10, 229-238.
168. Sheffield, J. K., and Jankovic, J. (2007). Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease. Expert Rev. Neurother. 7, 637-647.
169. Simola, N., Fenu, S., Baraldi, P. G., Tabrizi, M. A., and Morelli, M. (2004). Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp. Neurol. 189, 182-188.
170. Song, I. U., Kim, J. S., Ryu, S. B., An, J. Y., and Lee, K. S. (2008). Donepezil- induced jaw tremor. Parkinsonism. Relat. Disord. 14, 584-585.
171. Sovner, R., and Dimascio, A. (1977). The effect of benztropine mesylate in the rabbit syndrome and tardive dyskinesia. Am. J. Psychiatry 134, 1301-1302.
172. Spieker, S., Strole, V., Sailer, A., Boose, A., and Dichgans, J. (1997). Validity of long-term electromyography in the quantification of tremor. Mov. Disord. 12, 985-991.
173. Stacy, M., Silver, D., Mendis, T., Sutton, J., Mori, A., Chaikin, P., and Sussman, N. M. (2008). A 12-week, placebo- controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 70, 2233-2240.
174. Staude, G., Wolf, W., Ott, M., Oertel, W. H., and Dengler, R. (1995). Tremor as a factor in prolonged reaction times of parkinsonian patients. Mov. Disord. 10, 153-162.
175. Steinpreis, R. E., Baskin, P., and Salamone, J. D. (1993). Vacuous jaw movements induced by sub-chronic administra-tion of haloperidol: interactions with scopolamine. Psychopharmacology 111, 99-105.
176. Steinpreis, R. E., and Salamone, J. D. (1993). Effects of acute haloperidol and reserpine administration on vacuous jaw movements in three dif-ferent age groups of rats. Pharmacol. Biochem. Behav. 46, 405-409.
177. Stewart, B. R., Jenner, P., and Marsden, C. D. (1988). The pharmacological char-acterization of pilocarpine-induced chewing in the rat. Psychopharmacology (Berl.) 97, 228-234.
178. Stewart, B. R., Rose, S., Jenner, P., and Marsden, C. D. (1987). Pilocarpine- induced purposeless chewing behaviour in rats is dependent on intact central stores of 5-HT. Eur. J. Pharmacol. 142, 173-176.
179. Sung, Y. H., Chung, S. J., Kim, S. R., and Lee, M. C. (2008). Factors predicting response to dopaminergic treatments for resting tremor of Parkinson's disease. Mov. Disord. 23,137-140.
180. Tarsy, D. (1983). Neuroleptic-induced extrapyramidal reactions: classifica-tion, description and diagnosis. Clin. Neuropharmacol. 6, s9-s26.
181. Taylor, J. R., Lawrence, D. E., Redmond, J. D., Elsworth, J. D., Roth, R. H., Nichols, D. E., and Mailman, R. B. (1991). Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur. J. Pharmacol. 199, 389-392.
182. Threlfell, S., Clements, M. A., Khodai, T., Pienaar, I. S., Exley, R., Wess, J., and Cragg, S. J. (2010). Striatal mus-carinic receptors promote activity dependence of dopamine transmis-sion via distinct receptor subtypes on cholinergic interneurons in ventral versus dorsal striatum. J. Neurosci. 30, 3398-3408.
183. Timmer, J., Lauk, M., Pfleger, W., and Deuschl, G. (1998a). Cross-spectral analysis of physiological tremor and muscle activity. I. Theory and application to unsynchronized electromyogram. Biol. Cybern. 78, 349-357.
184. Timmer, J., Lauk, M., Pfleger, W., and Deuschl, G. (1998b). Cross-spectral analysis of physiological tremor and muscle activity. II. Application to synchronized electromyogram. Biol. Cybern. 78, 359-368.
185. Trevitt, J. T., Atherton, A., Aberman, J., and Salamone, J. D. (1998). Effects of subchronic administration ofclozapine, thioridazine and halop-eridol on tests related to extrapy-ramidal motor function in the rat. Psychopharmacology 137, 61-66.
186. Trevitt, J. T., Carlson, B. B., Correa, M., Keene, A., Morales, M., and Salamone, J. D. (2002). Interactions between dopamine D1 receptors and GABA mechanisms in substantia nigra pars reticulata: neurochemical and behav-ioral studies. Psychopharmacology (Berl.) 159,229-237.
187. Trevitt, J. T., Carlson, B. B., and Salamone, J. D. (1999). Behavioral assessment of atypical antipsychotics in rats: studies of the effects of olanzapine (Zyprexa). Psychopharmacology (Berl.) 145, 309-316.
188. Tronci, E., Simola, N., Borsini, F., Schintu, N., Frau, L., Carminati, P., and Morelli, M. (2007). Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antag-onist ST1535: acute and subchronic studies in rats. Eur. J. Pharmacol. 566, 94-102.
189. Vanover, K. E., Betz, A. J., Weber, S. M., Bibbiani, F., Kielaite, A., Weiner, D. M., Davis, R. E., Chase, T. N., and Salamone, J. D. (2008). A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol. Biochem. Behav. 90, 540-544.
190. Weinberger, M., Mahant, N., Hutchison, W. D., Lozano, A. M., Moro, E., Hodaie, M., Lang, A. E., and Dostrovsky, J. O. (2006). Beta oscillatory activity in the subthalamic nucleus and its rela-tion to dopaminergic response in Parkinson's disease. J. Neurophysiol. 96, 3248-3256.
191. Weiss, K. J., Ciraulo, D. A., and Shader, R. I. (1980). Physostigmine test in the rabbit syndrome and tardive dyskinesia. Am. J. Psychiatry 137, 627-628.
192. Wichmann, T., Kliem, M. A., and DeLong, M. R. (2001). Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian primates. Exp. Neurol. 167, 410-424.
193. Willner, P. (1990). "Behavioural models in psychopharmacology," in Behavioral Models in Psychopharmacology, ed. P. Willner (Cambridge: Cambridge University Press), 3-18.
194. Wilms, H., Sievers, J., and Deuschl, G. (1999). Animal models of tremor. Mov. Disord. 14, 557-571.
195. Wirshing, W. C., Cummings, J. L., Dencker, S. J., and May, P. R. (1989a). Electromechanical characteristics of tardive dyskinesia. J. Neuropsychiatry Clin. Neurosci. 3, 10-17.
196. Wirshing, W. C., Friedenberg, D. L., Cummings, J. L., and Bartzokis, G. (1989b). Effects of anticholin-ergic agents on patients with tar-dive dyskinesia and concomittant drug-induced parkinsonism. J. Clin. Psychopharmacol. 9, 407-411.
197. Wisniecki, A., Correa, M., Arizzi, M. N., Ishiwari, K., and Salamone, J. D. (2003). Motor effects of GABA (A) antago-nism in globus pallidus: studies of locomotion and tremulous jaw move-ments in rats. Psychopharmacology (Berl.) 170, 140-149.
198. Yassa, R., and Lal, S. (1986). Prevalence of the rabbit syndrome. Am. J. Psychiatry 143, 656-657.
199. Young, A., and Penney, J. (1993). Biochemical and functional organiza-tion of the basal ganglia, in Parkinson's Disease and Movement Disorders, eds J. Jankovic and E. Tolosa (Baltimore: Williams & Wilkins), 1-12.
200. Young, R. P. (1986). "Tremor," in Diseases of the Nervous System, eds A. K. Asbury, G. M. McKann, and M. I. McDonald (Philadelphia: W.B. Saunders), 435-451.
201. Zazpe, A., Artaiz, I., Innerárity, A., Del Olmo, E., Castro, E., Labeaga, L., Pazos, A., and Orjales, A. (2006). In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties. Neuropharmacology 51, 129-140.
202. Zhou, F. M., Wilson, C. J., and Dani, J. A. (2003). Muscarinic and nicotinic cho-linergic mechanisms in the mesostri-atal dopamine systems. Neuroscientist 9, 23-36.
203. Zigmond, M. J., Stricker, E. M., and Berger, T. W. (1987). "Parkinsonism: insights from animal models utilizing neu-rotoxic agents," in Animal Models ofDementia, ed. J.T. Coyle (New York: John Wiley and Sons, Inc.), 1-38.